KRAS and neoplasm: Optimized SYBR Green condition were then performed on the cohort of patients, subdividing them into four groups based on healthy and tumor tissues possessing WT KRAS (KRASGly12, Gly13) or mutated KRAS gene (KRASmut), corresponding to the different types of substitutions in Gly12 or Gly13.